Elite Pharmaceuticals Inc /NV/

Elite Pharmaceuticals, Inc. develops, manufactures, and commercializes generic and specialty pharmaceutical products, with a focus on controlled-release and abuse-deterrent formulations. The company also relies on licensing, marketing, and distribution arrangements, which means a meaningful part of its business depends on partners, a small number of products, and a concentrated customer base.

33,7 %

50,4 %

30,1 %

+77,1 %

6.45

5.22

— Elite Pharmaceuticals Inc /NV/
%
Generic pharmaceuticals55% Approved generic drug products sold through wholesalers, pharmacies, and other trade channels.
Controlled-release formulations20% Extended-release dosage forms designed to deliver active ingredients over time.
Abuse-deterrent products10% Products such as SequestOx™ intended to reduce abuse potential in opioid formulations.
Manufacturing and license revenue15% Revenue earned through manufacturing fees, profit splits, and commercialization agreements.

Elite sells primarily into a concentrated pharmaceutical channel rather than directly to end consumers...

  • Wholesalers and distributorsprimary

    Buy generic products in bulk for redistribution to pharmacies and other end customers; they matter because they control access to large downstream demand.

  • Retail drug chainsprimary

    Purchase products through negotiated contracts and influence pricing through consolidation and buying leverage.

  • Managed care organizations and insurersprimary

    Shape demand by steering utilization toward lower-cost generics and by pressuring pricing and rebates.

  • Group purchasing organizations and hospitalssecondary

    Buy through contract channels and drive chargebacks, rebates, and price concessions.

  • Collaborators and licenseessecondary

    Commercialize or distribute selected products and share economics with Elite under licensing arrangements.

Elite is a U.S.-based pharmaceutical company, and the available filings emphasize domestic regulatory, reimbursement,...

  • •Headquartered in the United States
  • •U.S. market is the core commercial and regulatory exposure
  • •Sales depend on domestic wholesalers, chains, and managed care
  • •FDA and DEA oversight are central to product approval and supply
  • •No country-level revenue disclosure was provided in the excerpts

Elite's strategy centers on developing and commercializing a small portfolio of differentiated generic and specialty...

01
Develop and launch new productsmedium-term

Future revenue depends on successful development, approval, and commercialization of product candidates.

02
Expand commercialization through partnersshort-term

Collaborators and licensees can extend market reach without requiring Elite to build a large direct sales force.

03
Defend pricing and access in concentrated channelsshort-term

Retail chains, wholesalers, and managed care organizations have significant bargaining power and can pressure margins.

Elite faces concentrated-product and concentrated-customer risk, which makes revenue vulnerable to the loss of a single...

high

Customer concentration

A small number of customers account for most revenue, so lost orders would quickly hit sales and cash flow.

Scope
Six largest customers accounted for over 80% of revenues
Materiality
high
high

Product concentration

Revenue depends on a limited number of products, increasing sensitivity to competition, regulation, or supply issues.

Scope
Top four product families exceeded 90% of allocated revenues
Materiality
high
high

Regulatory approval and compliance

Pharmaceutical products require FDA and DEA approvals and ongoing compliance, which can delay launches or restrict supply.

Scope
SequestOx™ NDA received a CRL; DEA quotas may limit ingredients
Materiality
high
high

Manufacturing interruption

Operations at a sole facility create a single point of failure for production and fulfillment.

Scope
Sole facility operations
Materiality
high
medium

Pricing and reimbursement pressure

Consolidated wholesalers, chains, and managed care buyers can demand discounts and rebates.

Scope
Chargebacks, rebates, allowances, and returns
Materiality
medium
medium

Litigation and IP disputes

Generic and controlled-substance products face patent, fraud-and-abuse, and product liability claims.

Scope
At-risk launches and infringement allegations
Materiality
medium
Variable consideration in revenue recognition
Can materially change quarterly and annual revenue
Chargeback and rebate reserves
Affects net sales and gross margin
Deferred tax assets and valuation allowance
Can affect tax expense and equity
Estimates for legal and regulatory contingencies
Can affect expenses and liabilities

Elite Health Systems Inc.

EHSI · Services-Specialty Outpatient Facilities, NEC

Olema Pharmaceuticals, Inc.

OLMA · Pharmaceutical Preparations

MIRA PHARMACEUTICALS, INC.

MIRA · Pharmaceutical Preparations

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA · Pharmaceutical Preparations

LFTD PARTNERS INC.

LIFD · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

: 28/04/2026